We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Judge Rules TKT Infringes Amgen Erythropoietin Patents

Law360 (October 16, 2004, 12:00 AM EDT) -- A federal judge has ruled in biotech company Amgen Inc.’s favor in its seven-year legal battle against Transkaryotic Therapies Inc. (TKT) and Aventis Pharmaceuticals Inc. over patents for an anemia treatment.

In a 290-page ruling, Judge William G. Young of U.S. District Court for the District of Massachusetts upheld four of Amgen's patent claims and said two of them had been infringed by TKT.

The patents cover the production of erythropoietin, a natural hormone produced by the kidneys that stimulates the production of red blood cells....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.